Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blinded, Placebo-Controlled Study on the Safety and Efficacy of Twice Daily Application of SM-030 Gel 0.64% Vs. SM-030 Gel 0.08% Vs. Placebo Gel in Adults With Melasma

NCT06454747 is registered in ClinicalTrials.gov with DermBiont, Inc. as lead sponsor.

NCT NCT06454747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06454747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blinded, Placebo-Controlled Study on the Safety and Efficacy of Twice Daily Application of SM-030 Gel 0.64% Vs. SM-030 Gel 0.08% Vs. Placebo Gel in Adults With Melasma
Lead sponsor
DermBiont, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 27, 2024
Completion date
October 31, 2025
Enrollment
138 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melasma